EVMN
HealthcareEvommune, Inc.
$15.37
$-1.94 (-11.21%)
Jan 5, 2026
Price History (1Y)
Analysis
Evommune, Inc. (EVMN) is a biotechnology company operating within the healthcare sector. With a market capitalization of $484.53M and annual revenue of $13.00M, it has a relatively modest scale compared to larger industry players. The company employs 45 individuals. Financially, Evommune exhibits significant net losses, with a net income (TTM) of -$62,823,000 and an EBITDA of -$71,386,000. Its operating margin is -133.3%, indicating substantial operating expenses relative to revenue. The company maintains a cash balance of $76.06M but has minimal debt, totaling $765,000. Valuation metrics for Evommune are negative across various ratios, including the forward P/E ratio and EV/EBITDA. This suggests that investors perceive the company's current financial performance as unfavorable or unprofitable at present.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Visit website →Key Statistics
- Market Cap
- $484.53M
- P/E Ratio
- N/A
- 52-Week High
- $24.03
- 52-Week Low
- $13.88
- Avg Volume
- 223.01K
Company Info
- Industry
- Biotechnology
- Exchange
- NYQ
- Country
- United States
- Employees
- 45